• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • NORTH AMERICA EDITION
      Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • NORTH AMERICA EDITION
      North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Minerals
    Tech
    Life Science
    Biotech Market
    Biotech News
    Biotech Stocks
    • Biotech Market
    • Biotech News
    • Biotech Stocks

    Is Intercept Pharmaceuticals Potentially up for Sale?

    Vivien Diniz
    Feb. 12, 2016 10:51AM PST
    Biotech Investing

    Reuters UK reported that Intercept Pharmaceuticals Inc is in the midst of exploring a potential sale after receiving interest from other companies, according to people familiar with the matter.

    Reuters UK reported that Intercept Pharmaceuticals Inc is in the midst of exploring a potential sale after receiving interest from other companies, according to people familiar with the matter.
    According to the article:

    Intercept has been working with investment bankers to explore the prospect of a sale, the people said this week, cautioning that there was no certainty on whether the company would decide to proceed with any transaction.

    Click here to view the full article on Reuters UK. 

    The Conversation (0)

    Go Deeper

    AI Powered
    Large pharmaceutical pill with gold dollar sign in the middle. Stock tickers and charts in the background.

    Top 5 Small-cap Pharma Stocks of 2025

    Pharma Outlook

    Pharma Outlook

    Latest News

    Appendix 4C and Quarterly Activities Report - September 2025

    Nextech3D.ai Reports Strong 20% Q2 Sequential Revenue Growth With Gross Margins of 88% For the Three Months Ended September 30, 2025 ("Q2 2026")

    Nextech3D.ai Reports Milestone YTD Revenue Growth for AI Matchmaking in 2025 with a 95% Gross Margin

    More News

    Outlook Reports

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
      • Electric Vehicles
    • Agriculture
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Energy
      • Uranium
      • Oil and Gas
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Robotics
      • Crypto
      • Cleantech
    Life Science
      • Biotech
      • Cannabis
      • Pharmaceuticals

    Featured Biotech Investing Stocks

    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES